Skip to main content

09-08-2018 | Rheumatoid arthritis | Review | Article

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

Current Rheumatology Reports

Authors: Sizheng Zhao, Laura Chadwick, Eduardo Mysler, Robert J. Moots

Publisher: Springer US


Purpose of Review

Adalimumab is one of the top-selling drugs worldwide. Its imminent patent expiration has seen the emergence of numerous biosimilar agents. In this article, we recap the evidence from bio-originator trials in rheumatoid arthritis (RA) to provide context for a critical review of biosimilar trial data.

Recent Findings

Currently, three adalimumab biosimilars are approved in Europe and/or the USA: Amgen’s ABP 501 (AMJEVITA/Solymbic), Boehringer Ingelheim’s BI 695501 (Cyltezo) and Samsung Bioepis’s SB5 (Imraldi). All three agents met their pre-specified equivalence criteria. Subtle differences in adverse events and clinical responses between the reference and biosimilar products were noted.


The introduction of adalimumab biosimilars will offer exciting opportunities in improving treatment access and increasing treatment options for RA and other licensed indications. Real-world data will further provide assurances on efficacy as well as safety.

Please log in to get access to this content

Related topics

EULAR 2020 E-Congress hub

Access the latest news and expert video commentary from the EULAR 2020 E-Congress.

Image Credits